Tissue Engineering Questions and Answers for Campus interviews focuses on “Development of Tissue-Engineered Human Skin Equivalents”.
1. The technology for epermal replacement (a confluent epithelial cell layer attached to a petroleum gauze carrier) was developed in the _______________
A. 1970s
B. 1990s
C. 2000s
D. 2010s
Answer: A
Clarification: The innovation for epermal substitution (a blended epithelial cell layer joined to an oilcloth transporter) was created during the 1970s. Shockingly, the pace of epermal engraftment was not exactly perfect and even effective cases showed poor toughness and frail epithelium.
2. The epermis is consered the outermost component of the skin and primarily comprised of ___________ a specific type of epithelial cells.
A. keratinocytes
B. collagen
C. stem cells
D. chondrocytes
Answer: A
Clarification: The epermis is viewed as the furthest segment of the skin and essentially involved keratinocytes, a particular kind of epithelial cells. The use of an epermal layer gives early restoration of a practical hindrance, which is crucial in the avoance of inordinate transepermal water misfortune and contamination.
3. The epermis is usually separated from a ____________
A. skin biopsy
B. grafting
C. replacement
D. regeneration
Answer: A
Clarification: So as to deliver an epermal skin substitution, the epermis is typically isolated from a skin biopsy, 2–5 cm2 in size, and keratinocytes are therefore refined on fibroblasts. Epermal Tess is sold by various organizations, for example, Genzyme’s Epicel® (Cambrge, MA, USA.. Epicel® is proposed for unions of consuming wounds and comprises of refined epithelium utilizing autologous epermal cells. Laserskin® (Fia Advanced Biopolymers Srl, Italy), is another epermal TES model assigned for the treatment of profound severe singeing and ceaseless ulcers.
4. Transcyte® is a non-living wound dressing produced by Advanced Tissue Sciences, Inc.
A. TRUE
B. FALSE
Answer: A
Clarification: Transcyte® is a non-living injury dressing delivered by Advanced Tissue Sciences, Inc. (La Jolla, CA, USA., which cryopreserves human dermal fibroblasts on a polymeric platform and has been built up as a reasonable brief injury dressing for extracted consume wounds. Dermagraft® is a subsiary of Transcyte® made by Advanced Biohealing and has shown the potential for treating diabetic foot ulcers (DFU).
Engineering for Campus Interviews,